TRYP THERAPEUTICS

CORPORATE PRESENTATION

SUMMER 2021

CSE: TRYP
OTCQB: TRYPF

DISCLAIMER

The information contained in this presentation (the "Presentation") has been prepared by Tryp Therapeutics Inc. ("Tryp" or the "Company") and contains information pertaining to the business, operations and assets of the Company. The information contained in this Presentation (a) is provided as at the date hereof and is subject to change without notice, (b) is for informational purposes only and does not purport to contain all information (including all material information) that may be necessary or desirable to fully and accurately evaluate the Company, and (c) is not to be considered as a recommendation by the Company that any person make an investment in Tryp. This Presentation does not constitute an offer to sell or solicitation of an offer to buy any of the securities of Tryp. The sole purpose of this Presentation, in paper or electronic form, is strictly for information purposes. Neither Tryp, nor any of its current or proposed directors, officers, owners, managers, partners, consultants, employees, affiliates or representatives, make any warranty or representation, whether express or implied, or assume any legal liability or responsibility for any action taken in reliance upon this Presentation, or for the accuracy, completeness, or usefulness of any information disclosed in this Presentation.

Forward Looking Information. This Presentation contains forward looking statements with respect to Tryp. By their nature, forward looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward looking statements. In addition, the forward looking statements require Tryp to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward looking statements will not prove to be accurate, that Tryp's assumptions may not be correct and that actual results may differ materially from such forward looking statements. Accordingly, readers should not place undue reliance on the forward looking statements. Generally, forward looking statements can be identified by the use of terminology such as "anticipate", "will", "expect", "may", "continue", "could", "estimate", "forecast", "plan", "potential" and similar expressions. Forward looking statements contained in this Presentation may include, but are not limited to statements with respect the outlook for the psilocybin industry and related industries; challenges and opportunities related to the psilocybin industry; the completion and timing of clinical studies; the ability of any patents resulting from Tryp's patent applications to protect the commercial prospects of its assets; the achievement, and the timing of, certain development milestones and the successful execution of Tryp's business strategy (including its business model and mission); the use and benefits of Tryp's products and services; demographic and market size/trends; forecasts of revenue and financial projections/growth potential; Tryp's ability to obtain marketing exclusivity for any of its approved drug products; anticipated capitalization, projected milestones and the go-forward management of Tryp; the potential impact of the COVID-19 pandemic on Tryp's business or operations; and other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance, expected regulatory filings, review and approval dates, and start-up timelines and schedules, and statements related to the continued overall advancement of Tryp's business. These forward looking statements are based on a number of assumptions which may prove to be incorrect including, but not limited to: general economic, market and business conditions, the outcome of research studies, the ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain sufficient capital on satisfactory terms, availability of equipment and supplies, changes in customer demand, the successful and timely implementation of capital projects, currency exchange rates and the impact of changes in applicable laws and regulations. The forward looking statements contained in this Presentation are made as of the date hereof or the dates specifically referenced in this Presentation, where applicable. Except as required by law, Tryp undertakes no obligation to update publicly or to revise any forward looking statements that are contained or incorporated in this Presentation. All forward looking statements contained in this Presentation are expressly qualified by this cautionary statement.

Third-Party Information. This Presentation includes market and industry data obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this Presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation as to the accuracy of such information. Some numbers in this Presentation may not be exact or add consistently due to rounding.

Electronic Form. This Presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the Company nor any director, officer, employee or agent of any of them or any affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the document distributed to you in electronic format and the hard copy version that may be made available to you.

Psilocybin. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug. While the Company is focused on developing products using psilocybin, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances. The Company does not currently manufacture, store or otherwise handle psilocybin directly and will only do so through agents within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products that contain psilocybin or other psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

OVERVIEW OF TRYP THERAPEUTICS

Tryp Therapeutics is a San Diego-based pharmaceutical company focused on developing psychedelic compounds targeting diseases with high unmet medical needs utilizing proprietary formulations.

Psilocybin-for-Neuropsychiatric Disorders (PFN™) Program

- **Chronic pain** including fibromyalgia, phantom limb pain, complex regional pain syndrome, and others
- **Eating disorders** including binge eating disorder, hypothalamic obesity, and others

TRYP THERAPEUTICS

- Our differentiated formulation confers potential safety and efficacy advantages to patients
- We intend to directly enter Phase 2a human clinical trials based on numerous past studies and the safety profile of our formulations
- We are focused on indications of high unmet medical needs and limited treatment options
- Our team has significant experience with developing and commercializing pharmaceutical compounds

After decades of stigma from the medical community due to the recreational use of psychedelic compounds, the FDA has recently granted Breakthrough Therapy Status to psychedelic compounds for medical indications.

This development follows the pattern of naturally derived substances such as aspirin from willow bark or penicillin from mold that are synthesized and then tested extensively through clinical trials for safety and efficacy.

"Psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine or the telescope is for astronomy."

– Stanislav Grof, M.D., Ph.D.



WORLD-CLASS SCIENTIFIC ADVISORS

Robin Carhart-Harris, Ph.D.
Global expert on use of psychedelics for medical indications

UCSF Imperial College London

Rachel Wervick, Ph.D.
Leading researcher in genetic development, including eating disorders

UNIVERSITY OF ALBERTA

Joel Castellanos, M.D.
Leading chronic pain researcher and physician

UC San Diego

Derek Ott, M.D.
Leading psychiatrist and Director of the UCLA Pediatric Neuropsychiatry Clinic

UCLA

William Schmidt, Ph.D.
Expert in drug development for pain indications

UCSF

MANAGEMENT TEAM

Greg McKee
Chairman and CEO

15+ years experience as CEO leading publicly traded biopharma companies and other organizations

Luke Hayes
Chief Financial Officer

20+ years of life science experience in finance, venture capital, business development, and technology transfer

Peter Guzzo, Ph.D.
VP, Drug Development

25+ years of experience developing innovative therapeutics for diseases with limited treatment options

Jim Gilligan, Ph.D.
President and Chief Science Officer

35+ years of experience including R&D, clinical development, regulatory affairs, and manufacturing

Tom D'Orozio
Chief Operating Officer

Extensive experience developing and commercializing vaccines, drugs, radiopharmaceuticals, and biologics

Larry Norder
VP, Manufacturing

30+ years of experience in the pharmaceutical industry including manufacturing and drug delivery

SIGNIFICANT NEED IN CHRONIC PAIN

The activity of **TRP-8802** and **TRP-8803** may make them effective in modulating chronic pain through action in the descending pain inhibitory pathway and increased neuroplasticity. We are investigating three initial pain indications:

Fibromyalgia

- Existing treatments for fibromyalgia (Lyrica, Cymbalta, and Savella) have limited efficacy and significant side effects with less than 10% of patients adhering to treatment after one year
- Nearly 30% of fibromyalgia patients take opioids despite the lack of evidence of their efficacy and the risk of addiction or overdose
- The fibromyalgia treatment market is expected to exceed $3.6 billion in value by 2026

Phantom Limb Pain (PLP)

- PLP results from neurologically initiated pain signals for appendages that no longer exist—a prime target for the application of psilocybin
- Existing treatment methods such as general pain medication, mirror therapy, and acupuncture have limited efficacy for many patients
- There are nearly 2 million patients in the US living with the loss of a limb with more than 60% experiencing PLP at some point

Complex Regional Pain Syndrome (CRPS)

- CRPS results from a misfiring of pain signals within the brain after an injury, surgery, stroke, or heart attack and is estimated to affect up to 250,000 people in the US

Coherent Market Insights, "Fibromyalgia Treatment Market to Surpass US$3,607.3 Million by 2026; https://www.amputee-coalition.org/; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0240431; https://www.jrheum.org/content/early/2017/07/26/jrheum.170098

EATING DISORDERS WITH HIGH UNMET NEEDS

TRP-8802 will be used to explore the treatment of eating disorders with **Jennifer Miller, M.D.,** of the University of Florida serving as the Principal Investigator for our initial Phase 2a clinical trial

Certain eating disorders including binge eating and hypothalamic obesity have limited treatment options and are expected to respond favorably to the neuroplasticity effects of TRP-8802

Jennifer Miller, M.D.
Professor, Division of Pediatric Endocrinology

UF UNIVERSITY of FLORIDA

Binge Eating Disorder (BED)

- BED is characterized by recurrent episodes of consuming large quantities of food and feeling unable to stop
- Up to 3.5% of females and 2.0% of males will develop BED*
- Nearly 30% of individuals looking for weight loss treatments show signs of BED*

Hypothalamic Obesity (HO)

- HO refers to obesity that is caused by damage to the hypothalamus, which makes hormones that control hunger
- The damage to the hypothalamus resulting in HO is often caused by the surgical removal of a brain tumor
- There are no FDA approved therapies specifically for HO

Tryp believes that TRP-8802's activity may make it effective in treating various eating disorders in combination with psychotherapy

** https://www.nationaleatingdisorders.org/statistics-research-eating-disorders*

CLINICAL TRIAL STRATEGY AND TIMELINE

- Tryp intends to seek approval from FDA to proceed directly into a Phase 2 clinical trial based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803
- We partner with leading academic institutions that have indication-specific expertise for our Phase 2a trials
- We expect to initiate at least two Phase 2a studies for our PFN™ program in 2021 with IND's submitted in 3Q 2021
- TRP-8803, our proprietary formulation with novel method of administration, will be used for our Phase 2b and Phase 3 clinical trials
- We have partnered with the University of Michigan to advance the development of TRP-8803 in preparation for its use in Phase 2b studies



PROPRIETARY MANUFACTURING

Tryp has entered into an agreement with **Albany Molecular Research Inc.** for research, development, and GMP manufacturing services for synthetic psilocybin that will form the basis of our **PFN™** program, including **TRP-8802.**

Tryp has engaged **Alcami** to develop the analytical methods and final formulations of its **TRP-8802** and **TRP-8803** products.

We expect to have our first batch of GMP product in **4Q 2021** representing the **only known supply of synthetic psilocybin that is produced in the United States.**

amri
Complex Science. Expert Solutions.

alcami

INTELLECTUAL PROPERTY

- Our **intellectual property**, including patent applications and trade secrets, is based on novel methods for the manufacturing, formulating, dosing, and administering of psychedelic compounds resulting in material benefits across multiple indications
- Tryp most recently filed a provisional patent in **March 2021** (US 63/161,070) describing innovative techniques resulting in a potential reduction in the time spent by patients in the dissociative state
- We have retained **Morrison & Foerster** to prosecute our patent applications

MORRISON
FOERSTER



COMPETITIVE LANDSCAPE: >$100 MILLION MARKET CAP COMPANIES

	PRECLINICAL	PHASE 1	PHASE 2a	PHASE 2b	PHASE 3
EATING DISORDERS			TRYP THERAPEUTICS, COMPASS		
PAIN		Beckley Psytech, TRYP THERAPEUTICS, MindMed			
PTSD			Bionomics		MAPS
ANXIETY	Cybin		MAPS, Bionomics, MindMed		
OTHER*	eleusis, Revive Therapeutics		COMPASS, atai, MindMed		
ADDICTION		MindMed, atai, Cybin		Awakn	Awakn
DEPRESSION		eleusis, Cybin, atai, Small Pharma		COMPASS, SEELOS	

** Includes body dysmorphic disorder (COMPASS), cognitive impairment (atai), ADHD (MindMed), Alzheimer's (Eleusis), TBI (Revive), and cancer (Revive); Sources: company press releases and websites*

ATTRACTIVE VALUATION RELATIVE TO PEER GROUP

	TRYP THERAPEUTICS	COMPASS	MINDMED	CYBIN	SEELOS	BIONOMICS
EXCHANGE / SYMBOL	CSE:TRYP	NASDAQ:CMPS	NEO:MMED	NEO:CYBN	NASDAQ:SEEL	ASX:BNO
MARKET CAPITALIZATION	$35M	$2.0B	$987M	$400M	$337M	$179M

CAPITAL STRUCTURE	
Issued and Outstanding	66,668,759
Warrant	9,361,019
Options and Comp Units	14,864,680
Fully Diluted	90,894,458

As of June 30, 2021; all figures in CAD

PROGRESS AND MILESTONES

Q1

Expanding our roster of world-class, **scientific advisors**

Adding members to Tryp's **executive team**

Expanding our **intellectual property** portfolio

Increasing funding with a **strategic investor**

Q2

Initiating collaborations with **world class research institutions** to advance clinical trials

Advancing our **manufacturing capabilities** for synthetic psilocybin

Q3

Announcement of several **new clinical research collaborations** with leading academic research institutes

Successful manufacturing and formulation of **GMP synthetic psilocybin** using our proprietary methods

Q4

Initiation of at least **two Phase 2a clinical trials in 2021**

Filing of **additional intellectual property applications**

1

We are addressing indications with critical, unmet medical needs that most psychedelic drug development companies are not.

2

We have the right scientific and executive team to successfully develop our drug platforms.

3

We have proprietary and differentiated methods for manufacturing, formulating, dosing, and administrating psychedelic compounds.

4

We intend to go directly into Phase 2a human clinical trials based on the safety profile of our chemistries.

TRYP THERAPEUTICS

TRYP
THERAPEUTICS

TRYPTHERAPEUTICS.COM

For questions, please contact:
investors@tryptherapeutics.com

CSE: TRYP
OTCQB: TRYPF

@tryptherapeutic